Literature DB >> 32044282

Genetic analysis of familial hypercholesterolemia in Asian Indians: A single-center study.

Nitika Setia1, Sireesha Movva2, Prahlad Balakrishnan2, Ishpreet K Biji2, Jitendra Pal Singh Sawhney3, Raman Puri4, Anjali Arora3, Ratna D Puri2, Renu Saxena2, Sanghamitra Mishra5, Sanika Apte5, Samarth Kulshrestha2, Vedam Lakshmi Ramprasad5, Ishwar C Verma6.   

Abstract

BACKGROUND: Familial hypercholesterolemia (FH), an autosomal codominant disorder characterized by very high low-density lipoprotein cholesterol, is strongly associated with premature coronary artery disease.
OBJECTIVES: Molecular landscape of FH in Asian Indians is not well studied, although this ethnic group comprises a large proportion of the world population. Knowledge of mutations in these groups is useful for identifying persons affected with FH, saving their lives, and cascade screening in their relatives.
METHODS: Potential cases of FH (n = 100) were identified by criteria adapted for the Indian population from Dutch Lipid Clinic Network criteria. Pathogenic variants were analyzed in LDLR, APOB 100 (exons 26 and 29), PCSK9, and APOE genes using Sanger sequencing and multiplex ligation-dependent probe amplification technique. Cases in whom there were no pathogenic variants were tested by next-generation sequencing using a targeted panel of genes.
RESULTS: Thirty-eight pathogenic variants were identified in 47 of 100 unrelated probands. Of these variants, 33 were identified in LDLR, 3 in APOB, and 2 in PCSK9 genes. Ten pathogenic variants were novel. Mutations were detected in 91.4% of those subjects classified as definite, 40% as probable, and in 18.8% as possible FH cases based on modified Dutch Lipid Clinic Network criteria. A likely founder mutation in intron 10 (c.1587-1G>A) of LDLR gene was observed in 6 North Indian families. The conventional pathogenic variants in APOB and PCSK9 genes and those previously reported in LDLR gene among Asian Indians were not detected in this cohort.
CONCLUSION: This study demonstrates genetic heterogeneity of FH in India. The variants observed were different from those described in Western populations. Next-generation sequencing technology helped identify new mutations in APOB gene, suggesting that in less-studied populations, it is better to sequence the whole gene rather than test for specific mutations.
Copyright © 2020 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APOB; APOE; Asian Indians; Familial hypercholesterolemia; Genetic analysis; LDLR; PCSK9

Mesh:

Substances:

Year:  2020        PMID: 32044282     DOI: 10.1016/j.jacl.2019.12.010

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  4 in total

1.  Healthcare worker-based opportunistic screening for familial hypercholesterolemia in a low-resource setting.

Authors:  Sonali Sharma; Ashish Khudiwal; Sonal Bhardwaj; Hemant Chaturvedi; Rajeev Gupta
Journal:  PLoS One       Date:  2022-06-09       Impact factor: 3.752

2.  Screening of PCSK9 and LDLR genetic variants in Familial Hypercholesterolemia (FH) patients in India.

Authors:  Lakshmi Lavanya Reddy; Swarup A V Shah; Chandrashekhar K Ponde; Jamshed J Dalal; Raj G Jatale; Reeta J Dalal; Rajesh M Rajani; Sudhir K Pillai; Chander V Vanjani; Tester F Ashavaid
Journal:  J Hum Genet       Date:  2021-04-16       Impact factor: 3.172

3.  The Prevalence and Genetic Spectrum of Familial Hypercholesterolemia in Qatar Based on Whole Genome Sequencing of 14,000 Subjects.

Authors:  Ilhame Diboun; Yasser Al-Sarraj; Salman M Toor; Shaban Mohammed; Nadeem Qureshi; Moza S H Al Hail; Amin Jayyousi; Jassim Al Suwaidi; Omar M E Albagha
Journal:  Front Genet       Date:  2022-07-15       Impact factor: 4.772

Review 4.  Shortcomings on genetic testing of Familial hypercholesterolemia (FH) in India: Can we collaborate to establish Indian FH registry?

Authors:  Lakshmi Lavanya Reddy; Swarup A V Shah; Tester F Ashavaid
Journal:  Indian Heart J       Date:  2021-12-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.